Monday . 2 August . 2021

*
The safety & scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.



Bạn đang xem: Huong tran

Gokhổng lồ
Top of Page Study Description Study Design Arms và Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct form size & cardiac remodeling in patients with axinh tươi myocardial infarction. Eligible patients will be randomly assigned lớn receive conventional therapy & single infusion of 1000U/kg of epoetin beta or conventional therapy alone. Infarct form size & cardiac remodeling parameters will be assessed by cardiac magnetic resonance imaging (MRI) within 3-7 days of the randomization & repeated 3 months later.
Condition or disease Intervention/treatment Phase
Myocardial Infarction Drug: EPO Phase 2

Goto lớn
Top of Page Study Description Study Design Arms và Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional (Clinical Trial)
ActualEnrollment : 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (mở cửa Label)
Primary Purpose: Treatment
Official Title: ErythroPOietin in Myocardial Infarction
Study Start Date : April 2008
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Resource link provided by the National Library of Medicine
Goto
Top of Page Study Description Study Design Arms & Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Xem thêm: Game Siêu Hùng Đại Chiến 6, Game Tính Điểm, Game Siêu Hùng Đại Chiến 6

Goto
Top of Page Study Description Study Design Arms và Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Primary Outcome Measures : Changes in infarct kích thước as assessed by magnetic resonance imaging 3 months after administration of study medication
Secondary Outcome Measures : End-systolic volume, end-diastolic volume, ejection fraction Changes in hemoglobin, platelets, reticulocytes blood count Occurrence of major cardiac sự kiện or venous thrombotic events
Top of Page Study Description Study Design Arms và Interventions Outcome Measures Eligibility Criteria Contacts & Locations More Information
Information from the National Library of Medicine Choosing lớn participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may liên hệ the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study: 18 Years & older (Adult, Older Adult)
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Inclusion Criteria:

ST-Segment elevation myocardial infarction Infarct related artery : proximal circumflex artery , proximal & mid left anterior descending artery, 1st segment of the right coronary artery TIMI 0 or 1 before angioplasty Successful PCI defined by residual stenosis Body weight : <50-110> kilogam Informed, written consent

Exclusion Criteria:

Age Pregnant, or parturient or breast-feeding women; Sexually active sầu women without efficient contraception; Inability lớn fully cooperate with the study protocol Pre-treatment with fibrinolysis ; Previous Q-wave myocardial infarction or previous aorto-coronary bypass; History of deep vein thrombosis or pulmonary embolism; Contraindication to lớn aspirin or clopidogrel ; Cardiogenic shoông chồng ; Cardiac resuscitated before angioplasty ; Past or active erythropoietin therapy; Contraindications to erythropoietin therapy: uncontrolled hypertension, known hypersensitivity lớn benzoic acid, chronic liver insufficiency, hemoglobin> 16g / l, thrombocytosis, refractory anemia with excess of blasts; Renal insufficiency (creatinine clearance Active Malignancies Any contraindications lớn magnetic resonance imaging: pacemaker & automatic cardiac defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in the eye, ferromagnetic haemostatic clips in the central nervous system cochlear implants, claustrophobia; Allergy to lớn gadolinium ; Patient refusal / patient not having provided written informed consent.
Top of Page Study Description Study Design Arms và Interventions Outcome Measures Eligibility Criteria Contacts & Locations More Information
Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study retìm kiếm staff using the tương tác information provided by the sponsor. Please refer to lớn this study by its 10kiem.vn identifier (NCT number): NCT00648089


Xem thêm: Tận Mắt Xem Loài Cá Mập Mèo Bông, Chơi Cá Cảnh

Layout table for location information
France
CHU Angers
Angers, France, 49933
Fabrice PRUNIER, MD, PhD,
Angers, France, 49933


Chuyên mục: Tin Tức